Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome

Sponsor
Guangzhou University of Traditional Chinese Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT00933725
Collaborator
(none)
194
8
2
22
24.3
1.1

Study Details

Study Description

Brief Summary

The purpose of this multiple-centered, randomized, controlled study is to investigate the efficacy and safety of a combination using herbs prescription and traditional Chinese medicine (TCM) emotion treatment in women with menopausal syndrome.

Condition or Disease Intervention/Treatment Phase
  • Other: TCM intervention
  • Other: Western intervention
Phase 3

Detailed Description

Menopausal syndrome is a high incident disease which is associated with great influence in women's health and quality of life. It involves physical discomforts and emotional symptoms. Traditional Chinese medicine (TCM) theory emphasizes treating physical and emotional symptoms simultaneously viewing one person as an entirety. Herbs prescription and TCM emotion treatment is effective and safe to treat women with menopausal syndrome in clinical practice.

Study Design

Study Type:
Interventional
Actual Enrollment :
194 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of Combined Treatment of Herbs and TCM Emotion Treatment for Women With Menopausal Syndrome: A Multiple-centered Randomized Controlled Trial
Study Start Date :
Aug 1, 2009
Actual Primary Completion Date :
May 1, 2011
Actual Study Completion Date :
Jun 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: TCM intervention

Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone

Other: TCM intervention
Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months. One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months. Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months.

Active Comparator: Western intervention

Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs

Other: Western intervention
Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months. Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months.

Outcome Measures

Primary Outcome Measures

  1. Kupperman index [2 months]

Secondary Outcome Measures

  1. blood serum estradiol [2 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
41 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 41-60;

  • Amenorrhea for at least 6 months;

  • Menstruation dysfunction or cessation because of age or bilateral ovariectomy;

  • Hot flushes and night sweats symptoms;

  • Vaginal secretion decreased with or without dyspareunia;

  • Kupperman Index (KI) score ≥ 15;

  • Self-rating Anxiety Scale or Self-rating Depression Scale standard score >50,but <72(standard score= scale score ×1.25);

  • FSH ≥ 20 IU/L;

  • Thickness of endometrium ≤0.5cm if Amenorrhea for at least 12 months;or ≤1.5cm if Amenorrhea for 6 months to 12 months;

  • Meet the diagnosis criteria of TCM syndrome of liver stagnation and kidney deficiency.

Exclusion Criteria:
  • With malignant tumor in reproductive system;

  • With benign tumor in reproductive system and need surgery;

  • Malignant tumor in mammary gland;

  • Irregular vaginal bleeding for unknown reasons;

  • Thickness of endometrium ≥1.5cm by ultrasound examination;

  • Have used Sex hormone medicine or joined other clinical trials 3 months before;

  • Allergy;

  • Severe diseases (eg., of the cardiovascular, liver, kidney) or uncontrolled endocrine diseases (eg., diabetes mellitus, hyperthyreosis )

  • Severe psychiatric disease diagnosed by psychiatric physician;

  • Refuse informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Foshan Hospital of Traditional Chinese Medicine Foshan Guangdong China 528000
2 Guangzhou University of Traditional Chinese Medicine Guangzhou Guangdong China 510120
3 Liwan Hospital of Traditional Chinese Medicine Guangzhou Guangdong China 510360
4 Affiliated Hospital of Hubei College of Traditional Chinese Medicine Wuhan Hubei China 430061
5 Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu Sichuan China 610075
6 Affiliated Hospital of Wenzhou Medical College Wenzhou Zhejiang China 325000
7 Longhua Hospital of Shanghai University of Traditional Chinese Medicine Shanghai China 200032
8 Baokang Hospital of Tianjin University of Traditional Chinese Medicine Tianjin China 300170

Sponsors and Collaborators

  • Guangzhou University of Traditional Chinese Medicine

Investigators

  • Principal Investigator: Xiaoyun Wang, Bachelor, Guangzhou University of Traditional Chinese Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guangzhou University of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT00933725
Other Study ID Numbers:
  • 2007BAI20B014
  • 2007BAI20B014
First Posted:
Jul 7, 2009
Last Update Posted:
Jun 18, 2012
Last Verified:
May 1, 2010
Keywords provided by Guangzhou University of Traditional Chinese Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2012